PMID- 37103055
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230501
IS  - 2308-3425 (Electronic)
IS  - 2308-3425 (Linking)
VI  - 10
IP  - 4
DP  - 2023 Apr 18
TI  - Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 
      Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese 
      Clinical Settings.
LID - 10.3390/jcdd10040176 [doi]
LID - 176
AB  - Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated 
      hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used 
      for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide is the 
      world's first oral GLP-1RA. This study aimed to provide real-world data on oral 
      semaglutide in Japanese patients with T2DM and its effects on cardiometabolic 
      parameters. This was a single-center retrospective observational study. We 
      examined changes in HbA1c and body weight (BW) and the rate of achieving HbA1c < 
      7% after 6 months of oral semaglutide treatment in Japanese patients with T2DM. 
      Furthermore, we examined differences in the efficacy of oral semaglutide with 
      multiple patient backgrounds. A total of 88 patients were included in this study. 
      Overall, the mean (standard error of the mean) HbA1c at 6 months decreased by 
      -1.24% (0.20%) from baseline, and BW at 6 months (n = 85) also decreased by -1.44 
      kg (0.26 kg) from baseline. The percentage of patients who achieved HbA1c < 7% 
      changed significantly from 14% at baseline to 48%. HbA1c decreased from baseline 
      regardless of age, sex, body mass index, chronic kidney disease, or diabetes 
      duration. Additionally, alanine aminotransferase, total cholesterol, 
      triglyceride, and non-high-density lipoprotein cholesterol were significantly 
      reduced from baseline. Oral semaglutide may be an effective option for the 
      intensification of therapy in Japanese patients with T2DM who have inadequate 
      glycemic control with existing therapy. It may also reduce BW and improve 
      cardiometabolic parameters.
FAU - Yamada, Hodaka
AU  - Yamada H
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, 
      Japan.
FAU - Yoshida, Masashi
AU  - Yoshida M
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, 
      Japan.
FAU - Funazaki, Shunsuke
AU  - Funazaki S
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, 
      Japan.
FAU - Morimoto, Jun
AU  - Morimoto J
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, 
      Japan.
FAU - Tonezawa, Shiori
AU  - Tonezawa S
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, 
      Japan.
FAU - Takahashi, Asuka
AU  - Takahashi A
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, 
      Japan.
FAU - Nagashima, Shuichi
AU  - Nagashima S
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, 
      Japan.
FAU - Masahiko, Kimura
AU  - Masahiko K
AD  - Department of Pharmacy, Jichi Medical University Saitama Medical Center, 1-847 
      Amanuma-cho, Omiya-ku, Saitama 330-8503, Japan.
FAU - Kiyoshi, Otsuka
AU  - Kiyoshi O
AD  - Department of Pharmacy, Jichi Medical University Saitama Medical Center, 1-847 
      Amanuma-cho, Omiya-ku, Saitama 330-8503, Japan.
FAU - Hara, Kazuo
AU  - Hara K
AD  - Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical 
      University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, 
      Japan.
LA  - eng
GR  - 19K18012/JSPS KAKENHI/
PT  - Journal Article
DEP - 20230418
PL  - Switzerland
TA  - J Cardiovasc Dev Dis
JT  - Journal of cardiovascular development and disease
JID - 101651414
PMC - PMC10141082
OTO - NOTNLM
OT  - cardiometabolic risk factors
OT  - glucagon-like peptide-1 receptor agonist
OT  - oral semaglutide
OT  - real-world data
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/27 12:41
MHDA- 2023/04/27 12:42
PMCR- 2023/04/18
CRDT- 2023/04/27 10:33
PHST- 2023/03/18 00:00 [received]
PHST- 2023/04/09 00:00 [revised]
PHST- 2023/04/16 00:00 [accepted]
PHST- 2023/04/27 12:42 [medline]
PHST- 2023/04/27 12:41 [pubmed]
PHST- 2023/04/27 10:33 [entrez]
PHST- 2023/04/18 00:00 [pmc-release]
AID - jcdd10040176 [pii]
AID - jcdd-10-00176 [pii]
AID - 10.3390/jcdd10040176 [doi]
PST - epublish
SO  - J Cardiovasc Dev Dis. 2023 Apr 18;10(4):176. doi: 10.3390/jcdd10040176.